Disc Medicine, Inc. Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase
Disc Medicine, Inc. (IRON) had Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase of 50.00% as of 2019-01-01, per its 10-K filed 2022-03-10.
Discontinued › Notes › Compensation Related Costs › Defined Benefit Plan › Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation
us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease · last filed 2022-03-10
- 2019-01-01: Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase 50.00%.
| Period end | Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase |
|---|---|
| 2019-01-01 | 50.00% 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |